Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Helyezés a részvények között #3122
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Részvényárfolyam
$93.47
Piaci kapitalizáció
$5.87B
Változás (1 nap)
2.32%
Változás (1 év)
428.05%
Ország
US
Kereskedés Kodiak Sciences Inc. (KOD)

Kategória

Healthcare
Kodiak Sciences Inc. (KOD) osztalékhozamának története
Kodiak Sciences Inc. (tőzsdei szimbólum: KOD) osztalékhozama (TTM) 2023-12-31 állapot szerint: 0.00%
Átlagos osztalékhozam az elmúlt 5 évben: 0.00%
Kodiak Sciences Inc. (KOD) osztalékhozamainak története 2016 és 2026 között
Éves záró osztalékhozam (TTM)
Év Osztalékhozam Változtassa meg
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
Hasonló cégek vagy versenytársak osztalékhozamai (TTM)
Vállalat Osztalékhozam Ország
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL